Improvement in both joint and skin symptoms reinforce TREMFYA® as a first-line treatment option with a proven safety profile for adults with active psoriatic arthritis BARCELONA, June 11, 2025 ...

Johnson & Johnson JNJ announced that the European Commission (EC) has approved an expanded use of its blockbuster psoriasis ...

TREMFYA ® demonstrated clinically meaningful and statistically significant efficacy in patients with active psoriatic arthritis at risk for structural damage in Phase 3b study Topline results ...

On Monday, Johnson & Johnson (NYSE:JNJ) announced results from the Phase 3 GRAVITI study of Tremfya (guselkumab) for Crohn’s disease. The findings demonstrated significant clinical remission and ...

The lowest effective recommended dosage should be used to maintain therapeutic response. The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adult patients ...

"Treatment with TREMFYA resulted in significant improvement in the chronic symptoms of ulcerative colitis, and importantly, normalization in the endoscopic appearance of the intestinal lining," said ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Johnson & Johnson’s Tremfya, a dual acting interleukin-23 inhibitor, for the treatment of ...

TREMFYA® is the only IL-23 inhibitor to demonstrate superiority to ustekinumab in the overall population of patients with Crohn's disease, inclusive of those who are biologic-naïve and ...

First-line treatment with TREMFYA® shows significant inhibition of radiographic progression at Week 24, which was sustained through Week 48, preserving joint health with a well-established safety ...

Additionally, for patients in the study's placebo group, who switched to TREMFYA ® at Week 24, the rate of radiographic progression from baseline to Week 24 (0.96) was reduced by 57% (to 0.41) from ...